Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

Second Edition: Travel4Expertise – The Grant for Caregivers

March 28, 2025Gender Equity Committee (GEC)

Call for Nominations – IUIS Elections 2025 – 2028

March 27, 2025

Join the IUIS-Junior Community symposium – Application for Short-talk Presentations Open!

March 26, 2025Early Career Committee (ECC)

IUIS/AAI AWARDS: Summer Courses in Immunology

March 21, 2025

In Memory of Fritz Melchers: A Visionary in Immunology

March 17, 2025

Using video to communicate science

March 7, 2025

Call for participation in the World Data System survey

February 18, 2025

Opportunity: The Club of Rome Communications Fellowship

February 18, 2025

Call for abstracts for the World forum for women in science 2025-Jordan

February 18, 2025